Skip to content

Author

Maximilian Stahl

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Sep 2026

Resistance mechanisms and therapeutic strategies after menin inhibitor failure in acute myeloid leukemia.

INTRODUCTION Menin inhibitors, including the FDA-approved agents revumenib and ziftomenib, have emerged as transformative targeted therapies in acute myeloid leukemia (AML), particularly in KMT2A-rearranged (KMT2Ar) and NPM1-mutated (NPM1m) disease. Despite high initial response rates, durability remains limited, and m...

A. Alhajahjeh, Maximilian Stahl, A. Zeidan et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.